Purple Biotech PPBT 深 沪
等待开盘 06-09 09:30:00 美东时间
2.86
-0.110
-3.70%
华盛通- 最 高2.99
- 今 开2.99
- 成交量 1.74万股
- 最 低 2.845
- 昨 收 2.97
- 总市值 329.00万
- 52周最高 29.00
- 市盈率 静 --
- 换手率 1.51%
- 52周最低 2.52
- 委 比 -69.37%
- 总股本 115.04万
- 历史最高 13900.00
- 量 比 3.20
- 振 幅 4.88%
- 历史最低 2.845
- 每 手 1
- 风险率 7.89%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Purple Biotech Files $200M Mixed Securities Shelf
https://www.sec.gov/Archives/edgar/data/1614744/000121390026059665/ea0291624-f3_purple.htm
05-21 05:43
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Silexion Therapeutics (NASDAQ:SLXN) shares moved upwards by 147.2% to ...
05-20 20:06
Earnings Scheduled For May 15, 2026
Companies Reporting Before The Bell • Traws Pharma (NASDAQ:TRAW) is expected to...
05-15 19:11
Purple Biotech GAAP EPS of -$0.09
Purple Biotech press release (PPBT): Q1 GAAP EPS of -$0.09. Adjusted Net Loss (as reconciled below) for the three months ended March 31, 2026, was $2.1 million, an increase of $0.8 million, compared t...
05-15 19:08
Purple Biotech Q1 EPS $0.09 Beats $(1.06) Estimate
Purple Biotech (NASDAQ:PPBT) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $(1.06) by 108.49 percent. This is a 105.29 percent increase over losses of $(1.70) per share from
05-15 19:07
Purple Biotech Announces Formation Of Advisory Board To Support Development of Its CAPTN-3 Tri-Specific Antibody Platform
Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer efficacy while minimizing
04-23 19:12
Purple Biotech Partners With Converge Bio Over Tri-Specific Antibody Platform
Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing
03-25 20:02
Purple Biotech Announces AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody Platform
Purple Biotech collaborates with Converge Bio to enhance its tri-specific antibody platform using AI, aiming to accelerate development and improve molecule quality for oncology targets. The partnership leverages Converge Bio's AI for faster, higher-quality drug discovery, targeting solid tumors. Purple's CAPTN-3 platform focuses on tumor-targeting antibodies engaging T and NK cells for improved efficacy and reduced toxicity. This collaboration co...
03-25 12:00
Purple Biotech regains compliance with Nasdaq
Purple Biotech (PPBT) has announced that it received confirmation from the Nasdaq that the Company had regained compliance with the minimum bid price requirement under Nasdaq rules for continued listi...
03-17 19:19
Purple Biotech Regains Compliance with Nasdaq
REHOVOT, Israel, March 17, 2026 – Purple Biotech Ltd. has regained compliance with Nasdaq's minimum bid price requirement, maintaining a $1.00 closing bid price for its ADSs for 10 consecutive business days, achieved on March 13, 2026. The Company, focused on developing next-generation immunotherapy platforms to maximize anti-cancer potency while minimizing toxicity, is advancing several candidates including IM1240, IM1305, CM24, and NT219. These...
03-17 11:00
